middle.news
Argent BioPharma broadens its antiviral strategy despite a thin cash balance
8:15am on Friday 23rd of October, 2026 AEDT
•
Biopharmaceuticals
Read Story
Argent BioPharma broadens its antiviral strategy despite a thin cash balance
8:15am on Friday 23rd of October, 2026 AEDT
Key Points
A$11,000 cash at 30 September after A$734,000 operating outflows
A$600,000 drawn under convertible securities facility during quarter
A$7.4 million of unused financing capacity at quarter end
Exclusive worldwide-ex-China rights to Tollovir, Tollovid and NutraVir
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE